Trafermin
As of the edition of 20 October 2026, Trafermin is a protein: marketed, first approved in 2001 (JP); acts on FGFR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2001
- Kind
- Protein
- Brand name
- Regroth Dental
- First approved
- 4 April 2001 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Nobelpharma; 2 holders in all
- Registered trials
- 4, 0 stopped early
- Disease areas
- Mouth and teeth; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Trafermin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FGFR2 | Fibroblast growth factor receptor 2 | P21802 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Kaken Pharmaceutical | Originator and Lead sponsor of trials | 2001 to now |
| Nobelpharma | Later holder | 2019 to now |